MaryO
-
Posts
8,078 -
Joined
-
Last visited
-
Days Won
552
Content Type
Profiles
Forums
Events
Blogs
Gallery
Articles
Media Demo
Store
Posts posted by MaryO
-
-
Engineered Vitamin D May Help Strengthen Bone
Mon Sep 30, 5:35 PM ET
By Linda Carroll
NEW YORK (Reuters Health) - Researchers have discovered a modified form of vitamin D that can help stimulate bone growth, a new study shows.
The compound may lead to new treatments for the brittle bone disease osteoporosis, according to the report published in the online early edition of the Proceedings of the National Academy of Sciences.
Scientists have long known that vitamin D is needed for healthy bones. But the naturally occurring form of the vitamin does not appear to play a direct role in bone formation, study co-author Hector F. DeLuca, chairman of biochemistry at the University of Wisconsin in Madison, said in an interview with Reuters Health.
DeLuca and his colleagues are studying a form of vitamin D called 2MD. "We and other groups have been modifying the molecule to get selective or improved action," he explained. "This compound is modified in three ways from the natural vitamin D hormone."
With the modifications, 2MD appears to boost bone growth by stimulating bone-building cells.
Like the skin, bone is continuously being destroyed and rebuilt. Bone-destroying cells, called osteoclasts, chew holes in bone. These cavities are then filled in by bone-forming cells, osteoblasts, using calcium as the building blocks. Up to age 30, bone-forming cells continue to work faster than bone-destroying cells. After that, osteoblasts slow down and bones start to thin.
In women, the thinning process accelerates at menopause when the ovaries stop producing estrogen.
DeLuca and his colleagues looked at the effects of 2MD on a rat model for menopause-related osteoporosis. The female rats in the study had had their ovaries removed. With no ovaries, the rats produced no estrogen.
For the new study, the researchers fed some of the rats vegetable oil with 2MD and some vegetable oil alone.
DeLuca and his colleagues measured the rats' bone density at the beginning of the study, at 13 weeks and at 23 weeks. At the end of the study, rats fed oil and 2MD had 9% more bone than those fed oil alone, DeLuca said.
The researchers also tested 2MD on human bone cells in the test tube. Once again they found that the vitamin led to bone growth.
The Wisconsin researchers aren't sure exactly how 2MD works. But DeLuca said the vitamin appears to affect both osteoclasts and osteoblasts. "It just seems to stimulate bone synthesis more," he said. "We're very excited about it as a potential therapy for bone-loss diseases."
The study was supported by the Wisconsin Alumni Research Foundation, Deltanoid Pharmaceuticals and the National Institutes of Health.
SOURCE: Proceedings of the National Academy of Sciences Early Edition 2002;10.1073/pnas.202471299.
-
http://story.news.yahoo.com/news?tm....omen_dc
Health - Reuters
Soy Cuts Insulin, Cholesterol in Diabetic Women
Mon Sep 30, 5:40 PM ET
By Suzanne Rostler
NEW YORK (Reuters Health) - Older women with type 2 diabetes who take a daily soy supplement show improvements in cholesterol and insulin levels, according to preliminary study findings.
Although the women took the supplements for only 12 weeks, the finding suggests that soy may reduce the risk of cardiovascular disease, such as heart attack and stroke, in women after menopause. There were no side effects associated with the supplements, researchers report in the October issue of Diabetes Care.
While larger and longer-term studies are needed, the results offer some hope to postmenopausal women with type 2 diabetes, who are up to four times more likely to die of heart disease than their healthy peers.
Recent study findings showing that the long-term risk of hormone replacement therapy (HRT) outweighs the benefits in postmenopausal women left many wondering where to turn for help.
For women with diabetes, the findings were all the more disappointing, Vijay Jayagopal, the study's lead author and a researchers at Hull Royal Infirmary in Hull, UK, told Reuters Health. Type 2 diabetes, the most common form of the disease, typically occurs in adulthood and is often associated with obesity.
"This fall from grace of HRT makes it even more important to focus on alternatives and the use of soy or soy-derived products therefore requires more urgent scrutiny," Jayagopal said in an interview. However, it is too soon to make any recommendations, since it is not clear how much soy is needed to provide cardiovascular protection and in what form it is most effective.
To investigate whether soy protein and isoflavones affected blood glucose (sugar), insulin, and other markers of heart disease risk, the researchers assigned 32 postmenopausal women with type 2 diabetes to take a soy supplement or an inactive pill (placebo) for 12 weeks. The dose of isoflavones--the antioxidant component of soy--was greater than amounts typically consumed in Asian countries, where rates of heart disease are lower and soy is a staple in the diet.
After 2 weeks in which all women consumed their regular diet, the study volunteers switched treatments for the next 12 weeks.
The women took a daily supplement containing 30 grams of soy protein plus 132 milligrams of isoflavones.
The soy supplement was associated with an 8% reduction in fasting insulin and an improvement in long-term blood glucose control, probably through its effect on total and LDL cholesterol, Jayagopal and colleagues conclude. Total cholesterol fell by about 4% and LDL cholesterol fell by 7%, 12 weeks after taking the daily soy supplement.
Chronically elevated levels of insulin, the body's key blood sugar-regulating hormone, raise the risk of both heart disease and exacerbate the effect of diabetes.
There was no effect on weight, blood pressure, HDL ("good") cholesterol, or triglycerides, a type of blood fat associated with heart disease. Similarly, the soy supplement did not appear to influence hormonal levels such as estrogen or testosterone.
"The findings of our study certainly provide an encouraging first step in answering some of the questions and provides hope for many postmenopausal women who are at risk of cardiovascular disease and at present have very few options in the way of therapeutic intervention to reduce this risk," Jayagopal said.
SOURCE: Diabetes Care 2002;25:1709-1714.
-
Anyone intested in any of these?
Fleece Pullover
Fleece Vest
Hooded Sweatshirt
Boxer Shorts
Infant/Toddler T-Shirt
Snap Bib
Sticker (Rectangular)
Sticker (Oval)
Lunchbox
Frosted Mug
Stein
Tile Coaster
Mousepad
Black Cap
Wall Clock
Small Poster
Large Poster
License Plate Frame
Flying Disc
BBQ Apron
Messenger Bag
Unistrap Bag
Briefcase
Metro Bag
Backpack
-
The iGive $5 bonus has been extended until 10/31/02.
Each new member means $5 extra for Cushing's Help and Support, on top of whatever they'd normally send!
Just go to this link:
http://www.iGive.com/html/refer.cfm?causeid=17825
There are now over 400 stores to choose from!
-
Thanks to everyone who uses iGive, I just got a check today for $34.99, through 6/30/2002.
A total so far of $174.44 has been sent to help run these boards and related websites: http://www.cushings-help.com (the main, informational site where the bios and other things are housed), http://www.cushings-support.com (message boards), http://www.cushingsonline.com (more storage space), http://www.CUSH.org (for the CUSH Organization) and http://www.CUSH.info (more CUSH Organization storage space)
So far the totals are (including money raised but not yet sent):
Total disbursed: $174.44
Total raised
...through shopping: $163.72
...through bonuses: $38.00
Grand total raised: $201.72
If you're not already a member, there's more info here
Thanks to everyone who participated in the program. ?Remember, it is of no cost to you!
-
Actually, he sent an real email, so I'm not sure if he intends to post or what.
-
Dr Blevins wrote:
Greetings. I hear from some of my patients who check out your site as a link from mine (www.pituitarycenter.com) and they find your site interesting and reassuring.
Just wanted to let you know that I have a book out on Cushing?s Syndrome that some of those who reach your site may find helpful. It can be purchased thru Amazon.com or any other medical textbook vendor. You might list it in the expensive (and perhaps confusing) books section. We think it is the best book out there on the subject. It is, by far, not complete but it is the best we could do given the publishers limitations.
Lewis Blevins
Director, The Pituitary Center at Vanderbilt
Remember - www.iGive.com contributes for books bought through Amazon...
-
09/23: AOL Health News: Study: Epilepsy Drug Helps Migraines
Study: Epilepsy Drug Helps Migraines
.c The Associated Press
WASHINGTON (AP) - The epilepsy drug topiramate appears to prevent migraine headaches - and unlike some other migraine medications that seem to attract pounds, its main side effect is weight loss, said a study released Monday.
Some 28 million Americans suffer from migraines, an intense, pulsing headache that can last hours, even days. There are a number of drugs sold to prevent migraines, but they don't work for everyone, so scientists are seeking new medications.
In recent years that search has included epilepsy drugs - after scientists discovered that migraines are not caused by the abnormal blood vessels once blamed but by a unique electrical disorder of brain cells.
Somewhat like epilepsy patient do, migraine sufferers have abnormally excitable brain nerve cells that, when triggered, fire across important pain centers to awaken nerve pain and inflame blood vessels.
Some drugs that fight epilepsy also suppress abnormal neuron firings, and one, Depakote, is often used as a migraine preventer. Now scientists have found that another epilepsy drug, topiramate, may be useful, too.
In a study of more than 400 migraine sufferers given varying doses of topiramate or dummy pills for four months, about half found their number and duration of migraines cut in half, said Dr. Stephen Silberstein of Thomas Jefferson University in Philadelphia. He was presenting his findings at a meeting of migraine researchers Monday.
The best-treated patients took 100 or 200 milligrams of topiramate a day, a lower dose than is used for epilepsy. But like in epilepsy patients, the migraine users experienced a side effect that would cause few to complain: weight loss. Patients lost, on average, 3.8 percent of their starting body weight, Silberstein said. For a skinny person that could be a problem, he acknowledged, but most patients in the study were overweight.
-
Hold those thoughts for 18 months, Lynne
-
Thanks, Angie!
-
At the time I was at NIH, that was one of the things that I liked about them. I honestly believed that I would die from my Cushing's, but I liked the idea that I would be possibly helping people who came after me. I agreed to all testing, just in case it would be helpful to others - some of it isn't done anymore, but I like to think of myself as a "pioneer".
I also don't think that being a part of a study at NIH gets a patient a cure any slower, either. They're a very caring bunch of folks and they move along as quickly as they can, while maintaining the integrity of care for all.
-
As a comment to Kristy - if they want to do something that's research only, you can always refuse to do it. They always tell you upfront, no surprises. Nothing is mandatory there. Even if they want to do testing or something that will help you, you can refuse that, too.
You are in control of what is done, and what isn't.
-
Carrie, it's not all that hard to get into, providing that you fit into their current protocol. Several people from the boards have gotten into NIH in the past few years. Off the bat I can think of Marie-Claude, Jane, Irene, Lisa Godwin, Spencer, Joy's daughter, Heidi, Jenny, Tim and I'm sure that there are some I'm forgetting.
They have wonderful, FREE! care, so I always encourage people to try for it - besides, you get to meet me LOL
-
Dearest has aways recommended Vitamin E on the Power Surge Recommendations Page
Here's some more good news about Vitamin E from http://story.news.yahoo.com/news?tm....ries_dc
Vitamin E May Help Keep Arteries Clear in Women
Mon Sep 9, 1:24 PM ET
NEW YORK (Reuters Health) - Women who take in less vitamin E may be at greater risk of heart disease and stroke, even if they do not have other risk factors, Italian researchers report.
Their study found that women with the greatest intake of vitamin E had the least plaque at the carotid bifurcation--a Y-shaped branch in the arteries in the neck where plaque build-up usually begins. This build-up, known as atherosclerosis, is a major risk factor for heart disease and stroke.
The findings suggest that vitamin E--found in nuts, olive oil and some vegetables--may provide protection against the early stages of plaque build-up, according to Dr. Paolo Rubba from Federico II University in Naples, Italy, and colleagues.
The study is published in the September issue of the American Journal of Clinical Nutrition).
Rubba and colleagues examined 310 women 30 to 69 years and measured their blood levels of vitamins A, C, E and other antioxidants. They also interviewed the study participants about their medical history, drug use and personal habits, and the frequency with which they consumed various foods. Women were then divided into three groups according to their intake of vitamin E-rich foods. None of the women were taking vitamin supplements.
Women who reported consuming the most vitamin E-rich food had the lowest build-up of plaque in their carotid bifurcation, the investigators found. Among postmenopausal women, those who consumed the least vitamin E were nearly three times more likely to have arterial plaque regardless of age, smoking habits, blood pressure, body mass index (BMI) and other heart disease risk factors.
Similarly, those with low blood levels of vitamin E relative to cholesterol were about twice as likely to have carotid plaques, the report indicates.
While the findings suggest an association between vitamin E intake and arterial plaque, it is still unclear exactly how vitamin E might prevent plaque build-up. Vitamin E is an antioxidant, meaning it neutralizes the effects of cell-damaging molecules called free radicals that may play a role in plaque formation. However, the study found no association between other antioxidant vitamins such as A, C and beta-carotene and arterial plaque.
More research is needed into vitamin E's potential plaque-fighting mechanisms, the researchers conclude.
SOURCE: American Journal of Clinical Nutrition 2002;76:582-587.
-
Hi and welcome to the boards!
I'm putting a copy of this post down on the Miscellaneous Tests Boards (just click here to get there), where people are more likely to see it and respond.
-
http://story.news.yahoo.com/news?tm....ow_dc_1
Argentina Cow Clone Step Toward Cheaper Growth Drug
Fri Aug 16, 5:20 PM ET
By Matias A. Loewy
BUENOS AIRES (Reuters Health) - The Spanish-speaking world now has its first cloned calf: "Pampa," a female born in Argentina last week.
The 37-kilogram Jersey calf was delivered by C-section after 278 days gestation and a global investment of $2 million.
Scientists who conducted the project consider Pampa's birth a step in the development of cloned and genetically modified cows capable of producing "more affordable" human growth hormone (hGH) and other expensive medicines, they said this week at a press conference.
This requires inserting the human gene responsible for producing the hormone into an embryo, theoretically making it possible for the mature animal to produce hGH in its milk. The birth of four calves containing the gene is expected in September, Dr. Carlos Melo, research and development manager at Bio Sidus, the company directing the research, told Reuters Health. But it will be some time before they can produce the hormone, Melo added.
"Within 4 years we may have a (decent number) of cows producing daily several grams of hGH in their milk," Melo told Reuters Health.
HGH from milk might be as much as 90% cheaper than the hGH now available, Melo told Reuters Health. In Argentina alone, some 1,000 children with dwarfism take the hormone daily to foster normal growth.
Pampa's birth places Argentina among the nine countries in the world capable of cloning livestock. The cloning technique involves removing the nucleus from a bovine egg cell and replacing it with the nucleus of a fetal cell-skin fibroblast, previously obtained from the animal to be copied.
In order to get pharmaceutical products from the milk, scientists must insert the human gene of interest into the embryo before implanting it into a surrogate mother cow.
An adult Jersey cow produces around 10 liters of milk a day, at least 200 days in the year. Bio Sidus expects that every single cloned cow would eventually produce 2 kilograms of raw hGH each year.
Once hGH is collected in the milk, scientists will have to purify and formulate it as medicinal product. "The whole process might imply losing around 50% to 80% of the original amount of the protein," Melo said. The product is not expected to reach the market before 2008.
Bio Sidus is already producing recombinant hGH by conventional bacterial fermentation, but cloning technology might allow the company to dramatically increase its current level of production.
In the future, Bio Sidus also plans to apply the technology to produce human tissue plasminogen activator (tPA), a potent clot-dissolving drug used to treat heart attack and stroke.
Bio Sidus SA is the biotech branch of the pharmaceutical group Sidus, founded in Argentina in 1938. The company manufactures five recombinant proteins, such as erythropoietin and filgrastim, and exports around 70% of its production to almost 40 countries.
-
http://www.washingtonpost.com/wp-dyn/artic...-2002Aug13.html
Hormone Replacement Gets New Scrutiny
Finding of Increased Risks Prompts Federal Effort
By Marc Kaufman
Washington Post Staff Writer
Wednesday, August 14, 2002; Page A01
Federal officials announced yesterday that they have begun a major reassessment of the risks and benefits of all combination hormone products containing estrogen used by post-menopausal women, one month after a large government study found potentially serious side effects from hormone replacement therapy.
The federal effort could change how popular drugs such as Prempro are advertised, prescribed and used, with new recommendations about who should take them, at what dosages and for how long.
The initiative, which will include several public forums this fall sponsored by the National Institutes of Health, the Food and Drug Administration and the Agency for Healthcare Research and Quality, will also try to guide future research on the suddenly more complex and controversial subject.
The move marks the first significant action by the federal government in response to the latest findings about hormone therapy. It is designed to address the widespread confusion that has caused anxious women to inundate doctors with questions about whether they should continue taking the powerful hormones.
"Somebody needed to take a leadership role, because there is chaos in the medical societies," said Wulf H. Utian, executive director of the North American Menopause Society, who has been invited to participate in the meetings. "It's time to clear the air and address the issues."
The brief announcement of the initiative came as the FDA separately pushed for immediate changes in the label and the package insert for the hormone combination sold as Prempro to reflect the risks confirmed by the Women's Health Initiative (WHI).
Part of that federally funded study was stopped three years early because of small but statistically significant increases in heart disease, breast cancer, stroke and blood clots among women taking Prempro, a combined estrogen-progestin drug. While the study used only Prempro, agency officials said they have new questions about other estrogen-progestin products on the market, as well.
In response to the immediate FDA concerns, officials at Wyeth Pharmaceuticals, maker of Prempro, said the company expects to submit new safety precaution information as early as this week that will take into account the WHI findings. The WHI study was testing the widely held hypothesis that hormone therapy reduced the risk for heart disease in particular and, so, was especially surprising.
"The FDA says it is our responsibility to get new information out there, and we agree," said Bruce Burlington, Wyeth's vice president for regulatory compliance. He said that many of the WHI findings on increased risks to women were already known and incorporated into the Prempro label but that "the risks were better quantified in WHI."
These initial steps can be taken without formal FDA approval. But officials said that they are aggressively reviewing hormone replacement therapy generally -- now used by 14 million menopausal and post-menopausal American women -- and that more wide-ranging changes can be expected.
As part of the effort, federal officials want to explore whether hormone therapies and their producers have encouraged women to believe menopause is a condition to be treated, rather than an inevitable and natural set of changes to be managed. The hormone therapy issue is being actively debated within medical societies, too, with the American College of Obstetricians and Gynecologists, the North American Menopause Society and others forming task forces on hormone replacement in response to the WHI findings.
Reflecting the FDA's discomfort with the way that hormone treatments have been widely presented as an antidote to menopause, the agency has told Wyeth to remove all references to "hormone replacement therapy" from its Prempro label. The "replacement" model, officials said, has never been accepted by the agency, which approved Prempro for specific symptoms of menopause and to prevent osteoporosis, a reduction in bone mass.
"The impact of the WHI findings [is] very far-reaching, and that fact is not lost on the FDA," said Florence Houn, a director at the FDA's Center for Drug Evaluation and Research. "As a public health agency, we need to step to the plate and reassess the risk-benefit conditions for labeling and risk management for patients."
Estrogen products have been used for decades and have helped millions of women handle the sometimes-severe symptoms of menopause, including hot flashes, night sweats, sexual discomfort and the increased risk of bone fractures.
For years, studies on heart disease, Alzheimer's, colon cancer and bone fractures also showed potential benefits to women taking hormone replacement long-term, and those findings were widely embraced by doctors and advertised by the drugmakers. The earlier positive findings on estrogen and heart disease, for instance, were considered strong enough by the American Heart Association to be included in its literature for women as recently as 1997.
But studies in the past several years began to raise doubts about the benefits and risks from long-term hormone therapy, and the large WHI study concluded that hormone therapy actually increased the risk of heart disease. That finding has required a quick pivot by medical authorities, individual doctors and, now, federal officials.
Further complicating the picture, the WHI study found that hormone therapy did help protect women against colon cancer and hip fractures. In addition, another arm of the WHI study did not find cardiovascular and cancer dangers with estrogen treatment alone (as opposed to the estrogen-progestin combination) when it was used by women who have had hysterectomies. That part of the study was allowed to continue.
The FDA expects to hold an expert advisory meeting this fall or winter to make recommendations about how hormone therapies should be used. Among the issues to be addressed are whether hormone treatment should be limited to several years, whether all hormone combinations containing estrogen carry the same risks, and whether estrogen-combination products require the kind of more prominent black box warnings that are used for drugs with potentially fatal side effects.
Although the WHI study did not find an increase in deaths from breast cancer, heart disease or stroke before it was stopped, the study did conclude that Prempro was associated with a greater risk of those diseases.
"Ultimately, the label that does get full FDA approval may well look quite different from what the company feels is needed for immediate strengthening," Houn said.
The FDA-approved label for a drug is key to how it is advertised, prescribed and used by patients. While doctors can write prescriptions off-label, companies can advertise to consumers and doctors only the uses approved by the FDA, and they must convey the side effects deemed serious by the agency.
Wyeth officials said that since the WHI study was discontinued, they have stopped direct-to-consumer advertising about hormone replacement but increased visits to doctors to explain the results.
? 2002 The Washington Post Company
-
http://www.acurian.com/patient....lcthtml
Summary: Androgen Replacement Therapy in Women with Hypopituitarism
This is a 12-month study investigating the effects of a natural hormone on bone formation, body composition, quality of life, cognitive function and libido. The study involves blood sampling, questionnaires and tests to determine bone density and the amount of fat and muscle in the body. Subjects will receive up to $600 for 6 outpatient visits after a screening visit determines eligibility.
Patient Inclusion/Exclusion Criteria:
Women ages 18-50 with adrenal insufficiency and/or estrogen deficiency from pituitary problems.
Contact:
Karen Miller MD
Massachusetts General Hospital
Fruit Street
Neuroendocrine
Boston, MA 02115
Telephone: 617-724-7388
Email: kkmiller@partners.org
~~~~~~~~~~~~~~~~~~~~~~
Center Overview
The Massachusetts General Hospital has a long, rich, and diverse tradition of excellence in clinical research that continues to expand today. The extensive resources for training clinical investigators and performing top quality translational investigation include: An integrated full service primary, secondary, and tertiary care hospital network with access to large numbers of both local patients with common diseases and national and international patients referred for evaluation of rare disorders, over 600,000 square feet of research space, and a diverse population of thousands of basic and clinical scientists studying topics ranging from very basic molecular biology to direct patient management.
The MGH Clinical Research Program (CRP) was established to improve the environment for clinical investigation at the MGH through academic enrichment programs and direct support services, creating a culture in which all forms of clinical research can flourish. Its mandate is to:
Enhance bench to bedside research
Train clinical investigators
Increase clinical trial activity
Support outcomes research and disease management
Coordinate the MGH's efforts with those of Partners HealthCare System and Harvard Medical School
The CRP serves as the institutional infrastructure that encourages and supports its physician scientists by serving as an interface between clinical investigators and sponsors of clinical trials and outcomes research. We work to:
Explore preferred relationships with pharmaceutical and biotech companies
Link industry to physicians for consulting, advisory board seats, and trials
Provide outcomes and disease management expertise
Support the administration of clinical trials
Negotiate master clinical trial agreements
The CRP provides a high level of clinical trial services to help investigators compete and meet the demands on industrial sponsors. Services to PIs include:
Assistance with the IRB application
Preparation and negotiation of budgets
Contact facilitation
Assistance in patient recruitment
Data management support
Assistance with strategy and proposal development for corporate-sponsored and investigator-initiated clinical trials
Assistance with the development of large multi-center grant applications
In addition to its role as a facilitator, the CRP has developed and sponsored a series of educational courses and seminars for current and future investigators and study coordinators. These activities not only improve the quality of the investigators and study coordinators but also raise awareness within the institution about clinical research. Mentoring is available to young researchers by fostering collaborations with established investigators. New investigators are offered career advice and assistance in developing and conducting research studies.
Since communication plays a critical role within the research community, the CRP has developed an interrelated set of communication and clinical research tools: CRnet an on-line information source about clinical research at MGH; web-based query tools and patient data registries to characterize patient populations and assess clinical trial feasibility; software and databases for investigator-initiated patient data registries and disease management studies; and direct technical support for the clinical investigative community.
The Clinical Research Program provides the infrastructure necessary to support clinical research on an institution-wide basis. By fostering academic collaboration, effecting communication with industrial sponsors and promoting a focused and streamlined administrative process, the CRP is building a responsive culture conducive to clinical investigation.
-
Wow, thanks for this, Kristy - I remember when Della's daughter died, we'd wondered what kind of pit tumor she'd had. I guess it wasn't Cushing's, but certainly scary enough!
I hope she continues to speak out about this. We need all the "talkers" we can get!
-
Anyone interested in any of these? ?You can see them, un-logo'd here
They're offering for "Back to School":
Backpack (black)
Metro Bag (black)
Unistrap Bag (black)
Briefcase (black)
Yellow Messenger Bag
Ash Grey Hoodie
Black Cotton Cap
Retro Lunch Box Coming later this month!
The black cotton caps and black bags are customized using a 4" x 2" patch with an embroidered edge.
Let me know, please, if there's any interest,,,
-
After I got rolling, it wasn't too hard. I should have planned ahead myself - I got my first t-shirt, totebag last week, then I went back and got some more stuff...then I ordered the travel mug with my name on it for Convention use.
I shudda waited, too, but I didn't want to miss the hat sale, either.
-
A variety of coffee mugs, including personalized and travel, are now available in the Cushing's Store ?There are currently 54 different products to choose from, all of which support these websites and CUSH.
I've made some with slogans to put on mugs for endos or other supportive people, but I'm open to other ideas if anyone has any thoughts...
-
The perfect place! Thanks, Sarah
-
I'm going nuts here. I just ordered another Tshirt for me (Cushing's Survivor), a Support Staff for Tom, a beach hat and... well, I really love my coffee, so I made myself a personalized travel mug. If anyone else would like something similar, just let me know.
If you're interested, you can see what I did here
Hats and Visors
in Cushing's Store
Posted
Coming Soon... any interest?:
Free Super Saver Shipping
Take advantage of the special shipping promotion this October. Until October 31, 2002, all orders over $40 will receive FREE Super Saver Shipping!